Skip to main content
ZheJiang Tailin Bioengineering Co.,Ltd logo

ZheJiang Tailin Bioengineering Co.,Ltd — Investor Relations & Filings

Ticker · 300813 ISIN · CNE100003S89 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2024-10-29 Report Publication Anno…
Country CN China
Listing Shenzhen Stock Exchange 300813

About ZheJiang Tailin Bioengineering Co.,Ltd

https://www.tailingood.com

ZheJiang Tailin Bioengineering Co.,Ltd. specializes in the research, development, and manufacturing of high-tech equipment for life sciences and pharmaceutical engineering. The company provides integrated solutions for microbial control, sterility testing, and aseptic processing. Its core product portfolio includes sterility test canisters and pumps, microbial limit testing systems, and hydrogen peroxide vapor (VHP) decontamination units. Tailin also develops advanced isolator technology for containment and aseptic applications, alongside analytical instruments such as Total Organic Carbon (TOC) analyzers and filter integrity testers. These products are designed to meet international regulatory standards, including GMP, USP, and EP. The company serves sectors such as biopharmaceuticals, medical devices, and laboratory research, focusing on product safety and quality through specialized engineering and microbial detection technologies.

Recent filings

Filing Released Lang Actions
关于2024年第三季度报告披露的提示性公告
Report Publication Announcement Classification · 100% confidence The document is a short announcement (331 characters) stating that the full 2024 third quarter report has been disclosed on an official website. It does not contain the actual financial data or report content but directs investors to where the report can be found. According to the 'MENU VS MEAL' rule, such a brief notice about the report's availability is classified as a Report Publication Announcement (RPA), not the report itself.
2024-10-29 Chinese
2024年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "浙江泰林生物技术股份有限公司2024 年第三季度报告" which translates to "Zhejiang Tailin Biotechnology Co., Ltd. 2024 Third Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and shareholder information for the third quarter of 2024. The document explicitly states it is a quarterly report and is unaudited. The length of the document (13,387 characters) and the presence of comprehensive financial statements confirm it is a substantive financial report rather than a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q3 2024
2024-10-29 Chinese
关于拟注销控股子公司沃锶达暨关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Zhejiang Tailin Biotechnology Co., Ltd. regarding the proposed cancellation (注销) of its controlling subsidiary, Beijing Wosida Cell Technology Co., Ltd., and the related party transaction involved. It includes details about the subsidiary, the board resolutions approving the cancellation, the rationale for the cancellation, financial data of the subsidiary, and compliance with relevant stock exchange rules. The document is a formal disclosure of a corporate action involving a subsidiary and related party transactions, but it does not contain comprehensive financial statements or detailed financial performance analysis of the parent company. It is not an annual or interim report, nor an earnings release or audit report. It is also not a management or governance report. The document is a regulatory announcement about a corporate restructuring event (subsidiary cancellation) and related party transaction. Given the content and length (2518 characters), it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-10-29 Chinese
关于取得专利证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Zhejiang Tailin Biotechnology Co., Ltd. regarding the acquisition of 16 patent certificates by the company and its subsidiaries. It lists patent details such as patent names, types, application numbers, and authorization dates. The document explicitly states it is an announcement about obtaining patents and does not contain financial data, management changes, voting results, or other report types. It is a regulatory announcement about intellectual property achievements, which does not fit into categories like Annual Report, Earnings Release, or Management Reports. Given the nature and length (1526 characters), it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2024-10-22 Chinese
关于2024年第三季度可转换公司债券转股情况公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the conversion of convertible bonds into shares for the third quarter of 2024 by Zhejiang Tailin Biotechnology Co., Ltd. It details the bond issuance, conversion prices adjustments, and the resulting changes in share capital. The document is structured as a formal announcement with specific data on bond conversions and shareholding changes, referencing regulatory compliance with Shenzhen Stock Exchange rules and China Securities Regulatory Commission approvals. It does not contain comprehensive financial statements or detailed financial performance analysis typical of an interim or annual report. It is not a full financial report but an update on convertible bond conversions and share capital changes. Therefore, it fits best into the category of Capital/Financing Update (CAP). The document length is 3538 characters, which is sufficient for a detailed announcement but not a full report. Hence, the classification is CAP with high confidence.
2024-10-08 Chinese
关于取得专利证书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Zhejiang Tailin Biotechnology Co., Ltd. about obtaining 8 patent certificates by the company and its subsidiaries. It lists patent details and states the impact on business operations. There is no financial data, no mention of financial results, no regulatory filings, no voting results, no management changes, no capital updates, no legal proceedings, and no other report types. The document is a regulatory announcement about intellectual property achievements, which does not fit into any specific financial report category. Therefore, it falls under the fallback category Regulatory Filings (RNS). The document length is short and it is a standalone announcement, not a report or presentation.
2024-09-10 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.